The overexpression membrane type 1 matrix metalloproteinase is associated with the progression and prognosis in breast cancer

American Journal of Translational Research

Volumn 7, Issue 1, 2015, Pages 120-127

  Li, Yongping ^a   Cai, Guohong ^b   Yuan, Shifang ^a   Jun, Yi ^a   Li, Nanlin ^a   Wang, Ling ^a   Chen, Feng ^c   Ling, Rui ^a   Yun, Jun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Breast cancer; Immunohistochemistry; Membrane type 1 matrix metalloproteinase; Prognosis

Indexed keywords

MATRIX METALLOPROTEINASE 14;

ADULT; AGED; ARTICLE; ATYPICAL DUCTAL HYPERPLASIA; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MRNA EXPRESSION ASSAY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84925378827     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bombonati A and Sgroi DC. The molecular pathology of breast cancer progression. J Pathol 2011; 223: 307-317.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Chaffer CL and Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
4. Murphy G and Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290-308.
5. Hadler-Olsen E, Winberg JO and Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol 2013; 34: 2041-2051.
6. Shuman Moss LA, Jensen-Taubman S and Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012; 181: 1895-1899.
7. Pahwa S, Stawikowski MJ and Fields GB. Monitoring and Inhibiting MT1-MMP during Cancer Initiation and Progression. Cancers (Basel) 2014; 6: 416-435.
8. Itoh Y and Seiki M. MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 2006; 206: 1-8.
9. Strongin AY. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 2010; 1803: 133-141.
10. Wang YZ, Wu KP, Wu AB, Yang ZC, Li JM, Mo YL, Xu M, Wu B and Yang ZX. MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer. Tumour Biol 2014; 35: 9815-21.
11. Ulasov I, Yi R, Guo D, Sarvaiya P and Cobbs C. The emerging role of MMP14 in brain tumorigenesis and future therapeutics. Biochim Biophys Acta 2014; 1846: 113-120.
12. Poincloux R, Lizarraga F and Chavrier P. Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009; 122: 3015-3024.
13. Sato H, Takino T and Miyamori H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci 2005; 96: 212-217.
14. Takino T, Guo L, Domoto T and Sato H. MT1-MMP prevents growth inhibition by three dimensional fibronectin matrix. Biochem Bio-phys Res Commun 2013; 436: 503-508.
15. Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV and Strongin AY. Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem 2002; 277: 9749-9756.
16. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H and Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001; 153: 893-904.
17. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M and Sato H. Cleavage of syndecan-1 by membrane type matrix metal-loproteinase-1 stimulates cell migration. J Biol Chem 2003; 278: 40764-40770.
18. Wali N, Hosokawa K, Malik S, Saito H, Miyaguchi K, Imajoh-Ohmi S, Miki Y and Nakanishi A. Centrosomal BRCA2 is a target protein of membrane type-1 matrix metalloproteinase (MT1-MMP). Biochem Biophys Res Commun 2014; 443: 1148-1154.
19. Zhou H, Wu A, Fu W, Lv Z and Zhang Z. Significance of semaphorin-3A and MMP-14 protein expression in non-small cell lung cancer. Oncol Lett 2014; 7: 1395-1400.
20. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P and Basset P. Membranetype matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci U S A 1995; 92: 2730-2734.
21. Wang H, Zhang X, Huang L, Li J, Qu S and Pan F. Matrix Metalloproteinase-14 Expression and Its Prognostic Value in Cervical Carcinoma. Cell Biochem Biophys 2014; 70: 729-34.
22. Udayakumar TS, Chen ML, Bair EL, Von Bredow DC, Cress AE, Nagle RB and Bowden GT. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res 2003; 63: 2292-2299.
23. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J and Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003; 106: 848-855.
24. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, Salovaara R, Nissen AM, Salo J, Mattson K, Hollmen J, Knuutila S and Wikman H. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004; 149: 98-106.
25. Crispi S, Calogero RA, Santini M, Mellone P, Vincenzi B, Citro G, Vicidomini G, Fasano S, Meccariello R, Cobellis G, Menegozzo S, Pierantoni R, Facciolo F, Baldi A and Menegozzo M. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One 2009; 4: e7016.
26. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J and Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 2005; 11: 481-483.
27. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C and Trudel D. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006; 8: R28.
28. McGowan PM and Duffy MJ. Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database. Ann Oncol 2008; 19: 1566-1572.
29. Zarrabi K, Dufour A, Li J, Kuscu C, Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S and Cao J. Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. J Biol Chem 2011; 286: 33167-33177.
30. Wu AW, Xu GW, Wang HY, Ji JF and Tang JL. Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database Syst Rev 2007; CD005047.
31. He L, Chu D, Li X, Zheng J, Liu S, Li J, Zhao Q and Ji G. Matrix metalloproteinase-14 is a negative prognostic marker for patients with gastric cancer. Dig Dis Sci 2013; 58: 1264-1270.
32. Peng CW, Wang LW, Fang M, Yang GF, Li Y and Pang DW. Combined features based on MT1-MMP expression, CD11b + immunocytes density and LNR predict clinical outcomes of gastric cancer. J Transl Med 2013; 11: 153.